Celyad SA (CYAD): Price and Financial Metrics
Today's Latest Price: $9.95 USD
Nov 27 12:15pm Add CYAD to Watchlist Sign Up
Buy & Hold Grade
Peer Grade Industry Rank
CYAD Stock Summary With a price/sales ratio of 20,807.91, Celyad Oncology SA has a higher such ratio than 99.89% of stocks in our set. With a year-over-year growth in debt of 529.59%, Celyad Oncology SA's debt growth rate surpasses 96.55% of about US stocks. As for revenue growth, note that CYAD's revenue has grown 94.83% over the past 12 months; that beats the revenue growth of 94.36% of US companies in our set. Stocks that are quantitatively similar to CYAD, based on their financial statements, market capitalization, and price volatility, are VNRX, TGTX, EIDX, AUPH, and PSTI. CYAD's SEC filings can be seen here. And to visit Celyad Oncology SA's official web site, go to www.celyad.com.
CYAD Price/Volume Stats
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
CYAD Latest News Stream
All News Types
Commentary Corp. News Earnings Mgmt Change New Coverage (Bullish) Product News PT Lowered PT Raised Rating Reiterated (Bullish) Stock Offering
Loading, please wait...
Latest CYAD News From Around the Web
Below are the latest news stories about Celyad Oncology SA that investors may wish to consider to help them evaluate CYAD as an investment opportunity.
Celyad Oncology SA (CYAD) First Half 2020 Earnings Conference Call August 07, 2020 8:00 AM ET Company Participants Filippo Petti – Chief Executive Officer David Gilham – Chief Scientific Officer Conference Call Participants Raju Prasad – William Blair Jim Birchenough – Wells Fargo Ed White – H.C. Wainwright Sandra Cauwenberghs...
Celyad (CYAD) gets the FDA's permission to begin a phase I study on its lead CAR T candidate, CYAD-211, for the treatment of relapsed/refractory multiple myeloma.
Calling it a "rebranding,", Celyad (CYAD) will now do business as Celyad Oncology. The ticker will remain as is....
The health care industry has been rallying so far this year on constant testing and COVID-19 vaccine trials.
Read More 'CYAD' Stories Here
CYAD Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.9889 seconds.